Concomitant Sjögren’s Syndrome Was Not Associated with a Poorer Response or Outcomes in Ursodeoxycholic Acid-Treated Patients with Primary Biliary Cholangitis

Table 2

Biochemical response to UDCA at 1 year.

	PBC(N=226)	PBC/SS(N=56)	P value
Paris-II response	144(63.7%)	34(60.7%)	0.677
Paris-I response	153(67.7%)	40(71.4%)	0.591
Toronto response	163(72.1%)	44(78.6%)	0.328
Barcelona response	147(65.0%)	41(73.0%)	0.246

SS, Sjögren’s syndrome; PBC, primary biliary cholangitis.